These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Does anti-IgE therapy help in asthma? Efficacy and controversies. Avila PC Annu Rev Med; 2007; 58():185-203. PubMed ID: 17059361 [TBL] [Abstract][Full Text] [Related]
29. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677 [TBL] [Abstract][Full Text] [Related]
31. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma. Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061 [TBL] [Abstract][Full Text] [Related]
32. Effect of omalizumab treatment in a baker with occupational asthma. Pérez Pimiento A; Bueso Fernández A; García Loria J; Rodríguez Cabreros MI; Mosquera MR; García Cubero A J Investig Allergol Clin Immunol; 2008; 18(6):490-1. PubMed ID: 19123449 [No Abstract] [Full Text] [Related]
33. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079 [TBL] [Abstract][Full Text] [Related]
34. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Buhl R; Solèr M; Matz J; Townley R; O'Brien J; Noga O; Champain K; Fox H; Thirlwell J; Della Cioppa G Eur Respir J; 2002 Jul; 20(1):73-8. PubMed ID: 12166585 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab. Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192 [TBL] [Abstract][Full Text] [Related]
36. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments. Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898 [TBL] [Abstract][Full Text] [Related]
37. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001 [TBL] [Abstract][Full Text] [Related]
38. [Retrospective analysis of omalizumab in patients with severe allergic asthma]. Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103 [TBL] [Abstract][Full Text] [Related]
39. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements. Hamilton RG J Allergy Clin Immunol Pract; 2016; 4(2):366-8. PubMed ID: 26968963 [No Abstract] [Full Text] [Related]
40. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy. Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]